Objective To investigate the status quo of the off-label use in patients with major mental disorders in a tertiary psychiatric hospital and to analyze its relevant risk factors,so as to provide the basis for establishing the off-label use norm.Methods The data of inpatients with major mental disorders (schizophrenia,bipolar disorder and depression) were collected from electronic medical records system in the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital).The incidence and categories of off-label use were analyzed by descriptive analysis.The chi-square test and logistic regression analysis were used to analyze factors such as age,gender,diagnosis,the number of prescribed psychotropic drugs,physician title,etc.Results A total of 2 371 patients and 10 794 prescriptions were collected and analyzed.The incidence of off-label use was 80.43％ (1 907/2 371) and 42.46％ (4 583/10 794) in patients and prescriptions,respectively.The main categories and constituent ratio of off-label use were indications (89.16％,4 086/4 583),dosage (4.63％,212/4 583),population and age (0.31％,14/4 583),while there were 5.91％ (271/4 583) prescriptions contain 2 or more different categories.The off-label use was widespread among different types of psychotropic drugs,mental disorders and clinical departments.The risk factors were the number of prescribed psychotropic drugs (Wald=177.218,P＜0.01),the diagnosis of mental disorders (Wald=35.320,P＜0.01) and physician title (Wald=8.667,P=0.003).Conclusion Off-label use is common in patients in the tertiary psychiatric hospital,involving different kinds of psychotropic drugs,mental disorders and clinical departments.The primary category of off-label use is indications.

Objective To investigate the status quo of the off-label use in patients with major mental disorders in a tertiary psychiatric hospital and to analyze its relevant risk factors,so as to provide the basis for establishing the off-label use norm.Methods The data of inpatients with major mental disorders (schizophrenia,bipolar disorder and depression) were collected from electronic medical records system in the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital).The incidence and categories of off-label use were analyzed by descriptive analysis.The chi-square test and logistic regression analysis were used to analyze factors such as age,gender,diagnosis,the number of prescribed psychotropic drugs,physician title,etc.Results A total of 2 371 patients and 10 794 prescriptions were collected and analyzed.The incidence of off-label use was 80.43％ (1 907/2 371) and 42.46％ (4 583/10 794) in patients and prescriptions,respectively.The main categories and constituent ratio of off-label use were indications (89.16％,4 086/4 583),dosage (4.63％,212/4 583),population and age (0.31％,14/4 583),while there were 5.91％ (271/4 583) prescriptions contain 2 or more different categories.The off-label use was widespread among different types of psychotropic drugs,mental disorders and clinical departments.The risk factors were the number of prescribed psychotropic drugs (Wald=177.218,P＜0.01),the diagnosis of mental disorders (Wald=35.320,P＜0.01) and physician title (Wald=8.667,P=0.003).Conclusion Off-label use is common in patients in the tertiary psychiatric hospital,involving different kinds of psychotropic drugs,mental disorders and clinical departments.The primary category of off-label use is indications.

ObjectiveTo investigate the efficacy of raltitrexed combined with transcatheter arterial chemoembolization (TACE) in the treatment of advanced colorectal cancer with liver metastasis. MethodsA total of 80 patients with liver metastasis of advanced colorectal cancer who were admitted to Central Hospital of China National Petroleum Corporation and underwent surgery from January 2012 to June 2015 were enrolled and randomly divided into study group and control group, with 40 patients in each group. The patients in the study group underwent hepatic arterial infusion chemotherapy with raltitrexed combined with TACE, and those in the control group were treated with intravenous infusion of raltitrexed alone. The above treatment was performed once every 4 weeks for 3-6 cycles. The response rate (RR), disease control rate (DCR), median time to disease progression, survival rate, and reductions in carcinoembryonic antigen (CEA), CA19-9, aminotransferases, and bilirubin were observed in the two groups. The chi-square test was used for comparison of categorical data between groups. ResultsRR, DCR, and the median time to disease progression showed significant differences between the study group and the control group (45.0% vs 22.5%, χ2=4.528, P=0.033; 70.0% vs 47.5%, χ2=4.178, P=0.041; 17.9 months vs 10.5 months, χ2=2408, P＜0.001). The study group had significantly higher 1- and 2-year survival rates than the control group (80.0% vs 57.5%, χ2=4.713, P=0.030; 55.0% vs 32.5%, χ2=4.114, P=0.043). The study group had a significantly higher number of patients with more than 50% reductions in CA19-9, CEA, aminotransferases, and bilirubin at 2 months after TACE than the control group (χ2=5333, 4528, 5051, and 5.013, P=0.021, 0.033, 0.025, and 0.025). ConclusionRaltitrexed combined with TACE is of good value in the treatment of advanced colorectal cancer with liver metastasis and holds promise for clinical application.